Latest Report Update: Jul 8, 2021

U.S. - Biological Products - Market Analysis, Forecast, Size, Trends And Insights
Update: COVID-19 Impact

Licenses

You will receive a PDF copy of the report by email within 24 hours (Mon - Fri).

By clicking «Buy the Report», you agree to our Terms of Service, Privacy Policy and Licenses. We'll occasionally send you account related emails.

Article Publishing Date: Jul 10, 2020

Biological Product Market in the U.S. to Post Solid Gains Amid the COVID Pandemic

IndexBox has just published a new report: 'U.S. - Biological Products - Market Analysis, Forecast, Size, Trends and Insights'. Here is a summary of the report's key findings.

For the seventh year in a row, the U.S. biological product market recorded growth in sales value, which increased by 11% to $50.4B in 2019. Overall, consumption continues to indicate a remarkable increase. The growth pace was the most rapid in 2018 when the market value increased by 27% against the previous year. Over the period under review, the market attained the maximum level in 2019 and is expected to retain growth in the immediate term.

The main biological products are vaccines, immune serums, and blood products. The main application of antisera is the use of it as an antidote to a snake or insect venom. Serum consumption is highly dependent on the bite occurrence and the welfare of the state, as lower-income countries cannot afford to sufficiently finance the purchase of antisera. 

Due to its powerful economy and high incomes, the U.S. is one of the leaders in the world in the consumption of antisera, the need for which is determined by the number of venomous animal bites and the population. Since the volume of serum consumption in the U.S. is already at a high level, and the demand for them is quite stable, a sharp increase in the consumption of serum in the medium term is not expected.

A vaccine is a biological preparation that improves immunity to a particular disease. Since vaccination plays a key role in the health policy of most countries in the world, these issues are under the scrutiny of WHO and national health services. Each country regulates the turnover of vaccines, their development, and permission for use. The vaccine consumption, therefore, is mainly determined by public immunization programs of the population as part of the preventive measures of the health system.

The overall market growth was primarily driven by growth in sales of hepatitis vaccines, and higher sales of influenza products and particularly from the introduction of new types of vaccines by key market players. Another impact came from the market growth in new patient populations now covered by immunization recommendations. As an example, in the U.S., some vaccines were previously licensed from 10-25 years old, but in 2018 they received Breakthrough Therapy Designation from the FDA for children from 2-10 years old. In the medium term, it is expected that major pharmaceutical companies will continue to innovate and lobby for the expansion of vaccination programs in the United States, which will contribute to market growth.

In addition, population growth, including immigration, should also buoy the increase in demand for biological products. The U.S. Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC) regulations require that all immigrant applicants receive a medical exam. During the exam, applicants are required to show proof that they have received certain vaccines. If an applicant does not have proof of having received the required vaccines, the law states that the vaccines must be given at the time of the medical exam. Over the last few years, a flow of migrants arrived in the United States, particularly from the Latin American countries. Among those people, there is a high probability of a lack of confirmation of the necessary vaccination, which will force the authorities to vaccinate migrants, which will increase the demand for vaccines and other biological products.

Market Forecast to 2030 

In early 2020, the global economy entered a period of the crisis caused by the COVID-19 epidemic, due to which most countries in the world put on halt production and transport activity. The result will be a drop in GDP relative to previous years and an unprecedented decline in oil prices. So far, the uncertainty regarding quarantine measures and the depth of the global economic decline is too great to make reliable forecasts. IMF states that even a short-lived outbreak would lead to at least a 3% contraction of the global GDP.

The U.S. is expected to face an even deeper short-term recession, with the contraction of GDP of approx. -5.9% in 2020, as the hit of the pandemic, was harder than expected, and unemployment soared due to the shutdown and social isolation. In the medium term, should the pandemic outbreak end in the second half of 2020, the economy is to start recovering in 2021 and then return to the market trend of the gradual growth, driven by the fundamentals existed before 2020 and boosted by support measures imposed by the government.

The biological product market, however, is one of the few markets where the demand is increasing amid the pandemic. The use of blood plasma from patients with antibodies to coronavirus to treat other patients is one of the currently available kinds of therapy for COVID-19. In addition, the development of a vaccine against coronavirus constitutes a super-urgent task. The largest companies and research organizations around the world are working on this task, including in the USA. Mass vaccination is cautiously expected to begin in 2021, leading to a notable increase in the vaccine and biological product markets.

Should this be the case, market performance is forecast to accelerate, expanding with an anticipated CAGR of +5.2% for the period from 2019 to 2030, which is projected to bring the market volume to 134K tonnes by the end of 2030. This tangible growth may be conditioned by the assumption that approx. 20% of the population may be vaccinated against coronavirus during the first year. 

When the negative consequences of the epidemic will start to fade out, it is expected that demand will gradually decline in the immediate term. It is too early to state that the consumption of the anti-coronavirus vaccine should wane because it’s not clearly known how long the vaccine-based immunity lasts.

Production in the U.S.

In value terms, biological product production rose sharply to $33.4B in 2019. The total output value increased at an average annual rate of +6.7% from 2013 to 2019; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The most prominent rate of growth was recorded in 2015 when the production volume increased by 15% against the previous year. Over the period under review, production attained the maximum level in 2019 and is likely to see steady growth in the immediate term.

Imports into the U.S.

In 2019, after six years of growth, there was a significant decline in overseas purchases of biological products, when their volume decreased by -11.2% to 20K tonnes. In general, total imports indicated a strong growth from 2013 to 2019: its volume increased at an average annual rate of +7.1% over the last six years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. The most prominent rate of growth was recorded in 2014 with an increase of 30% y-o-y. Over the period under review, imports attained the peak figure at 22K tonnes in 2018, and then shrank in the following year.

In value terms, biological product imports skyrocketed to $42.9B (IndexBox estimates) in 2019. Over the period under review, imports, however, continue to indicate significant growth. The pace of growth was the most pronounced in 2018 when imports increased by 40% y-o-y. Imports peaked in 2019 and are likely to see steady growth in the immediate term.

Imports by Country

In value terms, the largest biological product suppliers to the U.S. were Ireland ($11.5B), Germany ($8.6B) and Belgium ($4.4B), with a combined 57% share of total imports. The UK, Austria, France, Denmark, Canada, China, Mexico, New Zealand and Brazil lagged somewhat behind, together accounting for a further 10%.

Among the main suppliers, Brazil (+66.4% per year) saw the highest rates of growth with regard to the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Product coverage:
• Prodcom 21202120 -
• Prodcom 21202140 -
• Prodcom 21202145 - Vaccines for human medicine
• Prodcom 21202160 - Vaccines for veterinary medicine
• Prodcom 21106055 - Human blood, animal blood prepared for therapeutic, p rophylactic or diagnostic uses, cultures of micro-organisms, t oxins (excluding yeasts)
• Prodcom 21202320 - Blood-grouping reagents

This report provides an in-depth analysis of the biological product market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2025.


Country coverage:
• USA

Data coverage:
• Market volume and value
• Per Capita consumption
• Forecast of the market dynamics in the medium term
• Trade (exports and imports) in the U.S.
• Export and import prices
• Market trends, drivers and restraints
• Key market players and their profiles

Reasons to buy this report:
• Take advantage of the latest data
• Find deeper insights into current market developments
• Discover vital success factors affecting the market
This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.

In this report, you can find information that helps you to make informed decisions on the following issues:
1. How to diversify your business and benefit from new market opportunities
2. How to load your idle production capacity
3. How to boost your sales on overseas markets
4. How to increase your profit margins
5. How to make your supply chain more sustainable
6. How to reduce your production and supply chain costs
7. How to outsource production to other countries
8. How to prepare your business for global expansion
While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.
1. INTRODUCTION

Making Data-Driven Decisions to Grow Your Business

1.1
REPORT DESCRIPTION
1.2
RESEARCH METHODOLOGY AND AI PLATFORM
1.3
DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
1.4
GLOSSARY AND SPECIFIC TERMS
2. EXECUTIVE SUMMARY

A Quick Overview of Market Performance

2.1
KEY FINDINGS
2.2
MARKET TRENDS
3. MARKET OVERVIEW

Understanding the Current State of The Market and Its Prospects

3.1
MARKET SIZE
3.2
MARKET STRUCTURE
3.3
TRADE BALANCE
3.4
PER CAPITA CONSUMPTION
3.5
MARKET FORECAST TO 2030
4. MOST PROMISING PRODUCTS

Finding New Products to Diversify Your Business

4.1
TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
4.2
BEST-SELLING PRODUCTS
4.3
MOST CONSUMED PRODUCT
4.4
MOST TRADED PRODUCT
4.5
MOST PROFITABLE PRODUCT FOR EXPORT
5. MOST PROMISING SUPPLYING COUNTRIES

Choosing the Best Countries to Establish Your Sustainable Supply Chain

5.1
TOP COUNTRIES TO SOURCE YOUR PRODUCT
5.2
TOP PRODUCING COUNTRIES
5.3
TOP EXPORTING COUNTRIES
5.4
LOW-COST EXPORTING COUNTRIES
6. MOST PROMISING OVERSEAS MARKETS

Choosing the Best Countries to Boost Your Exports

6.1
TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
6.2
TOP CONSUMING MARKETS
6.3
UNSATURATED MARKETS
6.4
TOP IMPORTING MARKETS
6.5
MOST PROFITABLE MARKETS
7. PRODUCTION

The Latest Trends and Insights into The Industry

7.1
PRODUCTION VOLUME AND VALUE
8. IMPORTS

The Largest Import Supplying Countries

8.1
IMPORTS FROM 2007–2020
8.2
IMPORTS BY COUNTRY
8.3
IMPORT PRICES BY COUNTRY
9. EXPORTS

The Largest Destinations for Exports

9.1
EXPORTS FROM 2007–2020
9.2
EXPORTS BY COUNTRY
9.3
EXPORT PRICES BY COUNTRY
10. PROFILES OF MAJOR PRODUCERS

The Largest Producers on The Market and Their Profiles

LIST OF TABLES
Table 1:
Key Findings In 2020
Table 2:
Market Volume, In Physical Terms, 2007–2020
Table 3:
Market Value, 2007–2020
Table 4:
Per Capita Consumption In 2007-2020
Table 5:
Imports, In Physical Terms, By Country, 2007–2020
Table 6:
Imports, In Value Terms, By Country, 2007–2020
Table 7:
Import Prices, By Country Of Origin, 2007–2020
Table 8:
Exports, In Physical Terms, By Country, 2007–2020
Table 9:
Exports, In Value Terms, By Country, 2007–2020
Table 10:
Export Prices, By Country Of Destination, 2007–2020
LIST OF FIGURES
Figure 1:
Market Volume, In Physical Terms, 2007–2020
Figure 2:
Market Value, 2007–2020
Figure 3:
Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2007-2020
Figure 4:
Market Structure – Domestic Supply vs. Imports, In Value Terms, 2007-2020
Figure 5:
Trade Balance, In Physical Terms, 2007-2020
Figure 6:
Trade Balance, In Value Terms, 2007-2020
Figure 7:
Per Capita Consumption, 2007-2020
Figure 8:
Market Forecast To 2025
Figure 9:
Products: Market Size And Growth, By Type
Figure 10:
Products: Average Per Capita Consumption, By Type
Figure 11:
Products: Exports And Growth, By Type
Figure 12:
Products: Export Prices And Growth, By Type
Figure 13:
Production Volume And Growth
Figure 14:
Exports And Growth
Figure 15:
Export Prices And Growth
Figure 16:
Market Size And Growth
Figure 17:
Per Capita Consumption
Figure 18:
Imports And Growth
Figure 19:
Import Prices
Figure 20:
Production, In Physical Terms, 2007–2020
Figure 21:
Production, In Value Terms, 2007–2020
Figure 22:
Imports, In Physical Terms, 2007–2020
Figure 23:
Imports, In Value Terms, 2007–2020
Figure 24:
Imports, In Physical Terms, By Country, 2020
Figure 25:
Imports, In Physical Terms, By Country, 2007–2020
Figure 26:
Imports, In Value Terms, By Country, 2007–2020
Figure 27:
Import Prices, By Country Of Origin, 2007–2020
Figure 28:
Exports, In Physical Terms, 2007–2020
Figure 29:
Exports, In Value Terms, 2007–2020
Figure 30:
Exports, In Physical Terms, By Country, 2020
Figure 31:
Exports, In Physical Terms, By Country, 2007–2020
Figure 32:
Exports, In Value Terms, By Country, 2007–2020
Figure 33:
Export Prices, By Country Of Destination, 2007–2020

Webinar: Global Solid Biofuels Market - Statistics, Trends, and Outlook



Join our live webinar to get insights into the global solid biofuels market.



Thursday, September 9th, 2021 @ 04:00 pm ET


Register

Webinar: Global Beef Market - Statistics, Trends, and Outlook



Join our live webinar to get insights into the global beef market.



Thursday, September 16th, 2021 @ 04:00 pm ET


Register

Webinar: Global Cement Market - Statistics, Trends, and Outlook



Join our live webinar to get insights into the global cement market.



Thursday, September 23rd, 2021 @ 04:00 pm ET


Register
Ready to Get Started?
We can help you conduct market research and write a report using the most reliable data